JUNEL FE 1/20
Clinical safety rating
cautionComprehensive clinical and safety monograph for JUNEL FE 1/20 (JUNEL FE 1/20).
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
| Metabolism | Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation). |
| Excretion | Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal. |
| Half-life | Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days. |
| Protein binding | Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%. |
| Onset of Action | Oral: Contraceptive effect requires 7 days of continuous dosing; therapeutic effects on menstrual cycle begin within first cycle. |
| Duration of Action | 24 hours (daily dosing required); contraceptive protection persists as long as taken daily without missed doses. |
| Molecular Weight | 376.5 |
| Action Class | Combination hormonal contraceptive (estrogen-progestin) |
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable. |
| Pediatric use | Safety and efficacy not established in pediatric patients. Not indicated for use before menarche. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors. |
| 1st trimester | Avoid use; estrogen/progestin combinations are contraindicated in pregnancy due to risk of fetal harm and association with congenital anomalies. |
| 2nd trimester | Avoid use; may cause fetal harm, including potential effects on sex organ development. |
| 3rd trimester | Avoid use; may cause fetal harm, including potential effects on sex organ development. |
Clinical note
Comprehensive clinical and safety monograph for JUNEL FE 1/20 (JUNEL FE 1/20).
| Placental transfer | Estrogen and progestin components readily cross the placenta. |
| Breastfeeding | Estrogen and progestin are excreted in breast milk in small amounts. Use during breastfeeding may reduce milk production and quality. Consider alternative contraception if breastfeeding. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses). |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, liver function, and signs of thromboembolism. Fetal monitoring via ultrasound for growth and development if inadvertent exposure. |
| Fertility Effects | Normal ovarian function is suppressed during use, but fertility returns promptly after discontinuation. No evidence of permanent impairment of fertility. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Common Effects | Nausea, Vomiting, Headache, Breast tenderness, Breakthrough bleeding or spotting, Weight changes, Mood changes, Acne |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebral hemorrhage, Optic neuritis or retinal thrombosis |
PregnancyCurrent or history of thrombophlebitis or thromboembolic disordersCerebrovascular diseaseCoronary artery diseaseUndiagnosed abnormal uterine bleedingKnown or suspected breast cancerEstrogen-dependent neoplasiaLiver disease or impaired liver functionHeadache with focal neurological symptomsSmoking in women over 35 years of age
| Precautions | Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), Hepatic neoplasia (benign and malignant), Gallbladder disease, Hypertension, Carbohydrate and lipid metabolic effects, Headache, Bleeding irregularities, Depression, Ocular lesions (e.g., retinal thrombosis), Carcinoma of the breast and reproductive organs, Use in pregnancy (discontinue if pregnancy occurs) |
| Food/Dietary | No specific food restrictions. Grapefruit juice may theoretically increase estrogen levels but clinical significance is minimal; routine avoidance not required. Iron tablets (ferrous fumarate) may cause gastrointestinal upset; taking with food may reduce nausea. Avoid high-dose vitamin C supplements as they may increase estrogen absorption, but normal dietary intake is safe. |
| Clinical Pearls | Junel Fe 1/20 is a combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone 1 mg. It is a low-dose pill; efficacy may be slightly lower than higher-dose pills. The iron supplement (ferrous fumarate) in the placebo pills is not intended for contraception; patients should not skip active pills. Missed pills increase risk of ovulation; if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception for 7 days. Counsel on signs of venous thromboembolism (VTE): sudden leg pain, chest pain, shortness of breath. Consider alternatives in migraine with aura, uncontrolled hypertension, or smokers over 35. Drug interactions include rifampin, certain anticonvulsants (phenytoin, carbamazepine), and St. John's Wort which may reduce efficacy. |
| Patient Advice | Take one pill daily at the same time; the last 7 pills in each pack are iron tablets and do not provide contraception. · If you miss an active pill, take it as soon as you remember. If you miss two or more active pills, use a backup contraceptive method (e.g., condoms) for the next 7 days. · Vomiting or severe diarrhea within 4 hours of taking an active pill may reduce effectiveness; treat as a missed pill and consult your clinician. · Notify your clinician if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes. · Avoid smoking while on this medication, especially if over 35 years old, as it increases the risk of serious cardiovascular events. · Inform your clinician of all medications you take, including over-the-counter products and herbal supplements. |
Loading safety data…